Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
Status:
Terminated
Trial end date:
2021-04-29
Target enrollment:
Participant gender:
Summary
WVE-HDSNP2-002 is an open-label extension (OLE) study to evaluate the safety, tolerability,
PK, PD, and clinical effects of WVE-120102 in adult patients with early manifest HD who carry
a targeted single nucleotide polymorphism, rs362331 (SNP2). To participate in the study,
patients must have completed the Phase 1b/2a clinical study WVE-HDSNP2-001.